SecBot SecBot
8-K ·Filed Nov 9, 2026

FTH

Faeth Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed7d 13h ago SEC0001193125-26-452755
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The Phase 2 data provide a foundation for registrational trial design. Key catalysts to watch: disclosure of pivotal trial design by 1H 2027, data update at a medical meeting in mid-2027, and Phase 1b breast cancer data in 2H 2027.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$12.68
T+0 close · Nov 9, 2026 · via day close
Latest settled
−26.81%
T+5 · $9.28
Vs SPY
−25.12%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $12.68entry
  2. T+1 · 7d ago +1.89%α +2.26% · $12.92
  3. T+5 · 15h ago −26.81%α −25.12% · $9.28
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Faeth Therapeutics reported topline Phase 2 data for PIKTOR (serabelisib + sapanisertib) plus paclitaxel in advanced endometrial cancer, showing a 33% confirmed ORR and preliminary median PFS of 7.4 months in a heavily pre-treated population. The safety profile appears differentiated with low rates of hyperglycemia and stomatitis. The company plans to disclose a registrational trial design by 1H 2027.

Key Facts

  • Confirmed ORR of 33% (12/36) in efficacy-evaluable patients; DCR of 83%
  • Preliminary median PFS of 7.4 months (95% CI 5.3, NR) in all 42 treated patients
  • Preliminary 6-month PFS rate of 62% (95% CI 43, 75)
  • Confirmed ORR of 44% and DCR of 81% among patients with PIK3CA mutation
  • 2 of 42 patients (5%) discontinued due to treatment-related adverse events
  • All-grade hyperglycemia 12% (2% grade 3); all-grade stomatitis 21% (2% grade 3)
  • 16 of 42 patients remain on treatment; median duration of response not reached
  • Pivotal trial design expected by 1H 2027, subject to regulatory alignment

Financial Impact

U.S. TAM for 2L endometrioid endometrial cancer estimated at ~$2.5B; PIKTOR's price not yet set

revenue

Risk Factors

  • Single-arm Phase 2 study with small sample size (n=42); results may change with additional follow-up
  • Cross-trial comparisons only; no head-to-head trials conducted
  • PIKTOR is investigational and not yet approved by any regulatory authority
  • Regulatory alignment on pivotal trial design is not guaranteed
  • Company's ability to obtain additional capital to fund development

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-452755
Document: d19560d8k.htm0001193125-26-452755
Document: 0001193125-26-452755-index-headers.html0001193125-26-452755
Document: 0001193125-26-452755-index.html0001193125-26-452755
Document: 0001193125-26-452755.txt0001193125-26-452755

US Market Status

Market Closed · Opens Wed (11h 34m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026